Drug Discovery

The pharmaceutical industry has shifted toward multi-parameter optimization, testing every new molecular version for solubility and stability alongside its primary biological activity. This fundamental change marks the transition from simple screening to a highly disciplined engineering phase where

A comparative analysis using human blood cells revealed that these charge-switching lipids were the only delivery vehicles that did not provoke an immune response. This finding addresses the primary hurdle for wider medical application that has persisted since mRNA technology gained global fame:

Research from the MitoCarta Tree of Life project has revealed that mitochondria likely emerged late in the eukaryotic timeline after cells had already developed internal structures. This monumental finding comes from an extensive collaboration involving institutions like the Broad Institute of MIT

Addressing the risk of sarcopenia in patients using GLP-1 therapies has become a primary objective for researchers developing next-generation metabolic interventions. As the global pharmaceutical industry experiences a seismic shift toward metabolic health, the focus has broadened from achieving

Even after adjusting for age and prior therapy lines, metaplastic histology remains a clear indicator of a poor response to the Trop-2-directed antibody-drug conjugate sacituzumab govitecan. This finding, derived from a comprehensive retrospective analysis at the Massachusetts General Hospital

Introduction The landscape of neurological medicine is shifting rapidly as the U.S. Food and Drug Administration accelerates its evaluation of a potential breakthrough that could redefine how patients manage multiple sclerosis. This news centers on fenebrutinib, an investigational oral therapy that